The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Usefulness of l-[3-18f]-α-methyl tyrosine (18F-FAMT) PET as therapeutic monitoring for patients with advanced lung cancer.
Kyoichi Kaira
No relevant relationships to disclose
Tetsuya Higuchi
No relevant relationships to disclose
Noboru Oriuchi
No relevant relationships to disclose
Noriaki Sunaga
No relevant relationships to disclose
Takeshi Hisada
No relevant relationships to disclose
Takayuki Asao
No relevant relationships to disclose
Yoshihito Tsushima
No relevant relationships to disclose
Masanobu Yamada
No relevant relationships to disclose